ASCO 2022 | Use of opioid receptors as prognostic markers or therapeutic targets in urothelial carcinoma

Karim Chamie, MD, University of California Los Angeles, Los Angeles, CA, discusses the potential use of opioid receptors as prognostic markers or therapeutic targets in urothelial carcinoma, which may play a role in modulating tumor growth. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.